Mervan Tablet: Each film coated tablet contains Aceclofenac BP 100 mg.
Mervan SR Tablet: Each sustained release tablet contains Aceclofenac BP 200 mg.
Aceclofenac is a non-steroidal agent with marked anti-inflammatory and analgesic properties. The mode of action of aceclofenac is largely based on the inhibition to prostaglandin synthesis. Aceclofenac is a potent inhibitor of the enzyme cyclo-oxygenase, which is involved in the production of prostaglandins.
Aceclofenac is indicated for the relief of pain and inflammation of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, low back pain, dental pain, post-traumatic pain etc.
Other NSAIDs: Concomitant use of two or more NSAIDs (including aspirin) may increase the risk of adverse effects, including GI bleeding.
Anti-hypertensives: NSAIDs may reduce the effect of antihypertensives. Diuretics: Aceclofenac, like other NSAIDs, may inhibit the activity of diuretics.
Digoxin: NSAIDs may exacerbate cardiac failure, reduce GFR (glomerular filtration rate) and inhibit the renal clearance of digoxin, resulting in increased plasma digoxin levels. Lithium: Several NSAIDs inhibit the renal clearance of lithium. Methotrexate: Caution should be exercised if both an NSAID and methotrexate are administered within 24 hours of each other, since NSAIDs may increase plasma levels of methotrexate. Anti-coagulants: NSAIDs may enhance the effects of anti-coagulants, such as warfarin. Quinolone antibiotics: Patients taking NSAIDs and quinolones may have an increased risk of developing convulsions. Anti-platelet agents and selective serotonin reuptake inhibitors (SSRIs): If taken with NSAID, the risk of gastrointestinal bleeding may be increased.
Aceclofenac is contraindicated in patients with history of hypersensitivity reactions to ibuprofen, aspirin or other non steroidal anti-inflammatory drugs and also in patients with active or history recurrent peptic ulcer/haemorrhage.
The majority of adverse effects observed are of minor in nature and these include gastro-intestinal disorders such as dyspepsia, abdominal pain, nausea & diarrhea, dizziness, increase in hepatic enzyme etc. Undesirable effects may be minimized by using the lowest effective dose for the shortest duration.
Pregnant Women: It should be given in pregnancy only if the potential benefit justifies the potential risk to the foetus.
Lactating mother: Caution is advised when it is administered to a nursing women.
Geriatrics: Patients who are 65 years or older, caution should be taken to closely monitor blood cell counts during mesalazine therapy.
Patients with a history of gastrointestinal disorders or peptic ulceration, as well as those with severe liver or renal impairment should be under close medical supervision.